Avacta Group (LSE:AVCT) EBIT: £-29.07 Mil (TTM As of Dec. 2025)


LSE:AVCT Avacta Group PLC LSE:AVCT
28 GF Score
Price £0.72
GF Value £0.49
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Avacta Group EBIT?

Avacta Group LSE:AVCT +0.28% 28 EBIT is £-29.07 Mil as of Dec. 2025. GuruFocus rates LSE:AVCT with a GF Score™ of 28/100 and a GF Value™ of £0.49 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Avacta Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was £-16.11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was £-29.07 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Avacta Group's annualized ROC % for the quarter that ended in Dec. 2025 was -125.81%. Avacta Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,512.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Avacta Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -8.64%.

Avacta Group  (LSE:AVCT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Avacta Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-32.696 * ( 1 - 0% )/( (28.544 + 23.431)/ 2 )
=-32.696/25.9875
=-125.81 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=29.237 - 6.6 - ( 12.645 - max(0, 27.898 - 21.991+12.645))
=28.544

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=29.417 - 8.948 - ( 16.855 - max(0, 26.157 - 23.195+16.855))
=23.431

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Avacta Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-32.228/( ( (2.1 + max(0.591, 0)) + (1.57 + max(-5.396, 0)) )/ 2 )
=-32.228/( ( 2.691 + 1.57 )/ 2 )
=-32.228/2.1305
=-1,512.70 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.006 + 0 + 6.34) - (6.6 + 0 + 2.155)
=0.591

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.979 + 0 + 3.361) - (8.948 + 0 + 2.788)
=-5.396

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Avacta Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-29.068/336.354
=-8.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avacta Group EBIT Related Terms

Avacta Group EBIT Historical Data

* Premium members only.

The historical data trend for Avacta Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avacta Group EBIT Chart

Avacta Group Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.19 -39.04 -16.65 -19.13 -29.86

Avacta Group Semi-Annual Data
Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.96 -1.12 -18.01 -12.95 -16.11

LSE:AVCT vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Avacta Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avacta Group EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Avacta Group's EV-to-EBIT falls into.


LSE:AVCT
28GF Score
Avacta Group PLC LSE:AVCT
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avacta Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-29.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of £-29.07 Mil mean?
Avacta Group (LSE:AVCT) has a EBIT of £-29.07 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Avacta Group.
Is Avacta Group's EBIT too high?
Avacta Group's current EBIT is £-29.07 Mil. Overall, Avacta Group has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's EBIT compare to VRTX and REGN?
Avacta Group's EBIT of £-29.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Avacta Group. Avacta Group's current EBIT is £-29.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (LSE:AVCT) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.49, compared to a current price of £0.72 — trading 47.3% above its estimated fair value. The current EBIT is £-29.07 Mil. Avacta Group's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Avacta Group (LSE:AVCT), the current EBIT is £-29.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avacta Group (LSE:AVCT) Overvalued in 2026?

Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued. The current stock price of £0.72 is trading 47.3% above its estimated GF Value™ of £0.49. GuruFocus considers Avacta Group to be Significantly Overvalued.

Key valuation signals for LSE:AVCT:

  • EBIT: £-29.07 Mil
  • GF Value™: £0.49 vs. price of £0.72 (47.3% above fair value)
  • GF Score™: 28/100 with 8 warning signs

No single metric tells the full story. See the LSE:AVCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avacta Group Business Description

Other Exchanges AVCTF:USARTQ1:Germany
Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
28GF Score

Get the complete analysis for LSE:AVCT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.72
Price
£0.49
GF Value